Wednesday, August 10, 2022


Biotechnology News Magazine

Biotechnology News Magazine

Biotechnology News Magazine is one of the industry’s leading sources for biotech industry news!

Biotechnology News Magazine reports the latest biotech, pharma, FDA updates, biotechnology clinical trials, biotechnology mergers, biotechnology acquisitions, biotechnology funding, articles of interest and other important news.

Biotech executives, investors, and other allied health professionals have access to Biotechnology News Magazine through a complimentary subscription. Furthermore, as patients become more pro-active in researching various medical diseases and conditions, we are proud to boast they are subscribers of our publication as well.

We hope you find value in Biotechnology News Magazine’s overall purpose and objectives. BiotechnologyNews Magazine is the authoritative voice of biotechnology, bridging the industry to healthcare professionals, academia, government, venture capitalists, and the general public.

If you have any questions or comments, please feel free to contact us.

Biotechnology News Magazine is a fast, 1,2,3, easy read! LEARN MORE.

Latest Biotech Industry News

Akadeum Life Sciences Announces New Dead Cell Removal Kit Using Microbubble Technology

Akadeum Life Sciences advises that the new buoyant separation method creates a more effective way for researchers to use valuable samples with a higher retention rate of viable cells than current magnetic techniques.

Bio-Rad Extends Range of StarBright Violet and UltraViolet Dyes for Multiplex Flow Cytometry

StarBright Violet 760, StarBright UltraViolet 575, and StarBright UltraViolet 605 dyes conjugated to highly validated antibodies for multicolor panel design in immunology research.

Pear Therapeutics and SelectHealth Announce Coverage to Provide Access to FDA-Authorized Prescription Digital Therapeutic for the Treatment of Opioid Use Disorder

SelectHealth teams with Pear Therapeutics to provide its members with covered access to Pear’s innovative prescription digital therapeutic, reSET-O®, for the treatment of opioid use disorder as adjunct to outpatient treatment that includes transmucosal buprenorphine Medication-Assisted Treatment.

Persephone Biosciences Announces First Participant Enrolled in Proprietary My Baby Biome Study of Infant Gut Health

My Baby Biome study is an observational study to determine gut biomarkers associated with health outcomes in infancy and later life.

HERTHENA-Lung02 Phase 3 Trial of Patritumab Deruxtecan Initiated in Patients with EGFR-Mutated Metastatic Non-Small Cell Lung Cancer

Patritumab deruxtecan is currently being evaluated as both a monotherapy and in combination with other anticancer therapies. In addition to the HERTHENA-Lung02 trial, patritumab deruxtecan is being evaluated in HERTHENA-Lung01, a pivotal phase 2 trial in patients with EGFR-mutated locally advanced or metastatic NSCLC previously treated with a EGFR TKI and platinum-based chemotherapy; a phase 1 trial in combination with osimertinib in EGFR-mutated locally advanced or metastatic NSCLC; and a phase 1 trial in previously treated patients with unresectable or metastatic NSCLC. A phase 1/2 trial in HER3 expressing metastatic breast cancer also has been recently completed.

Thermo Fisher Scientific Launches Enhanced Applied Biosystems HIV-1 Genotyping Kit

The HIV-1 Genotyping Kit is designed to support the detection of the UNAIDS 2030 95-95-95 HIV targets, which aims to have 95 percent of people living with HIV to be diagnosed, 95 percent who are diagnosed to be receiving treatment, and 95 percent of those on treatment to be virally suppressed.

Creoptix Launches New WAVEcontrol Software

By combining the high sensitivity, throughput, and no-clog microfluidics of the WAVEsystem, with a faster, more flexible, automated approach to screening and characterization, Creoptix is accelerating biologics drug discovery and diagnostics development.

Sagimet Biosciences Announces Oral Presentation on Denifanstat at Keystone Symposia in Nonalcoholic Steatohepatitis (NASH)

Sagimet Biosciences advises the data will be presented at the Keystone Symposia: Inter Organ Crosstalk in NASH, held August 7-10, 2022 in Whistler, British Columbia

Vacmobile Joins Georgia Tech’s Advanced Technology Development Center’s Accelerate Startup Portfolio

Vacmobile offers unique, globally scalable, rapidly deployable solution.

FDA Grants Extension of Shelf-life & Expiration Date for GenBody COVID-19 Ag Test

This extension was granted after FDA review of long-term studies demonstrating that the GenBody tests maintain their performance long after the initially defined 12-month window notes GenBody America.

GenomOncology and Congenica Announce Collaborative Development of Novel Precision Oncology Solution

To further enrich decision support capabilities for this novel precision oncology solution, Congenica is collaborating with GenomOncology to provide regional therapy recommendations.

Launch of Novacyt’s 1st Fully Lyophilised PROmate Assays

Two PROmate® lyophilised assays initially launched for COVID-19, with a broader portfolio of lyophilised direct-to-PCR assays in development.

Noteworthy Views & Opinions from Our Experts

COVID-19 Accelerates Scientific Advancements in Other Areas

In this article, Charlie Rapple, co-founder of science communication platform Kudos, explores how COVID research has influenced recent scientific developments and why better dissemination of research helps empower people in the healthcare sector.

The Predictive Power of Functional Motion: By Dr. Frank Fornari, Chairmain and Founder, BioMech Labs

Dr. Fornari writes, "Advances in artificial intelligence, machine learning, mobile technologies, and real-time interactive biofeedback have made it possible to capture motion data in clinical and real-world settings and deliver precise, accurate and reproducible therapeutic assessments and treatments that stratify risk, improve outcomes, and increase the efficiency of the healthcare delivery system.

How Does Image Integrity Impact Scientific Research?

Image integrity issues can go unnoticed because it is difficult to manually review all the images in an article. The consequences of not detecting these issues, however, can be severely detrimental to a researcher’s reputation.

How to Disaster-Proof Your Manufacturing Business: By Steve Severaid, President of The Greenspan Co/Adjusters International

Constantly evolving supply chains and increasing extreme weather events have imposed significant risks for many large manufacturing facilities. When it comes to the biotechnology industry, there are additional obstacles associated with the complexities of the manufacturing process and its advanced equipment, sensitive inventory.

More Articles from the Experts

Clinical Trials, Studies, Data

Gamida Cell Announces Dosing of First Patient in Company-Sponsored Phase 1/2 Study of NK Cell Therapy Candidate GDA-201

“We are excited to further advance the development of GDA-201, a NAM-enabled natural killer (NK) cell therapy candidate which we believe has the potential to be a new readily available, cryopreserved treatment option for cancer patients with relapsed/refractory lymphoma,” said Ronit Simantov, M.D., chief medical and scientific officer of Gamida Cell.

Ceapro Inc. Announces Publication of Positive Results for PGX-Processed Alginates Impregnated with CoQ10 in The Journal of Supercritical Fluids

Ceapro highlights that PGX Technology continues to demonstrate the ability to generate superior novel bioactive delivery systems.

PureTech Founded Entity Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-2 Trial of KarXT in Schizophrenia

EMERGENT-2 Trial met primary endpoint, with KarXT demonstrating a statistically significant 9.6-point reduction in PANSS Total Score compared to placebo at Week 5 (p<0.0001).

EpicentRx Publishes Commentary in International Journal of Infectious Disease (IJID) on Need for a “Universal” Coronavirus Vaccine to be More Effective Against Novel Viral Variants

According to viral immunologist and EpicentRx CEO, Dr. Tony R. Reid, "We've already faced three coronavirus pandemics, starting with SARS CoV

FDA Updates

Trethera Announces FDA Orphan Drug Designation Granted to TRE-515 for the Treatment of Demyelinating Optic Neuritis

TRE-515 is a first-in-class drug targeting the enzyme deoxycytidine kinase (dCK).

B.More Submits FDA Investigational New Drug Application for Psilocybin Alcohol Use Disorder Program

According to Carey Turnbull, Co-founder and CEO of B.More, "B.More's psilocybin AUD program IND application is a major step forward in our mission to develop psychedelic medicines for individual struggling with alcohol use disorder. Our Phase 2b trial builds on the impressive work led by Dr. Bogenschutz and will provide vital data to further advance our drug development program."

Sandoz Supplemental Biologics License Application Accepted by US FDA for biosimilar Hyrimoz® (adalimumab-adaz) High Concentration Formulation (HCF)

Submission supported by comprehensive analytical data package and clinical Phase I pharmacokinetics bridging study reports Sandoz.


F2G Announces $70 Million Financing to Advance Development and Commercialization of New Antifungal Agent Olorofim

The proceeds from the financing in addition to the $480 million from the recent strategic collaboration with Shionogi & Co., Ltd., will enable F2G to advance late-stage development and commercialization in the US of olorofim, a novel oral antifungal therapy to treat invasive aspergillosis (IA) and other rare mold infections. Nanna Lüneborg of Forbion and Joe Anderson of Sofinnova Partners will join the F2G Board of Directors.

Kintara Therapeutics Enters Into Equity Purchase Agreement for Up to $20 Million with Lincoln Park Capital

Under the terms of and subject to satisfaction of the conditions contained in the agreement, Kintara will have the right in its sole discretion, but not the obligation, to sell to LPC up to $20 million worth of shares of its common stock from time to time over the 36-month term of the agreement

Eleven Therapeutics Announces $22 Million in Seed Funding

Eleven Therapeutics notes the round includes $9 Million from the Bill & Melinda Gates Foundation, aimed at ushering in the next generation of RNAi therapeutics.

Executives on the Move

Emmanuelle Toussaint Named Executive Director of BIOQuébec

Emmanuelle Toussaint was named one of Canada’s 100 Most Powerful Women in 2021 by the Women’s Executive Network.

Kathy Hopinkah Hannan Appointed to Ginkgo Bioworks BOD

Kathy Hopinkah Hannan brings over thirty years of experience as a senior C-Suite executive, corporate advisor, independent board director and strategist leading significant operations and high priority initiatives.

Market Reports

Health / Lifestyle Articles

Articles of Interest